Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First year growth response associated genetic
2011-000460-10Phase 4Completed
- Sponsor
- Merck Serono
- Start
- May 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of somatropin in idiopathic growth hormone deficiency (I-GHD), Turner syndrome (TS) and growth hormone deficiency (GHD), sponsored by Merck Serono. Primary endpoint: Genetic markers associated with first-year growth response. Started May 2011; status: completed.
02
Drugs
somatropin
03
Conditions
idiopathic growth hormone deficiency (I-GHD)Turner syndrome (TS)growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2011-000460-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000460-10.